

Publishable Summary

This deliverable is a descriptive report on amyloid PET scan quantification of all consecutive and valid participants that have been analyzed as of September 24th 2021 from the two AMYPAD trials. It includes data from 1121 PET scans from the Prognostic and Natural History Study (PNHS) and 823 patients from the Diagnostic and Patient Management Study (DPMS). All the analyses have been performed for the individuals whose amyloid PET imaging data passed quality control for the primary outcome variable (global cortical average normalized to the whole cerebellum). Therefore, this report covers the descriptive analysis and first major results of the PNHS and DPMS data.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.



innovative
medicines
initiative